Medical Center Comac Medical Ltd.
- Address
- lock Available on a paid plan
Digestive System Diseases
The research at Medical Center Comac Medical Ltd. includes detailed pharmacokinetic investigations to understand how liver and kidney conditions affect drug behavior, with a focus on therapies relevant to the digestive system.
- Impact of hepatic impairment on drug absorption and clearance
- Influence of renal impairment on drug exposure levels
- Safety and tolerability profiling in healthy volunteers
The site is conducting three trials with two investigators, examining agents such as AMX0035 and Camizestrant to improve treatment strategies for patients with liver or kidney dysfunction.
Clinical Pharmacology
This area concentrates on multiple‑dose studies that compare drug performance in participants with organ impairment versus healthy subjects, aiming to refine dosing recommendations.
- Multiple dose pharmacokinetic profiling in impaired renal function
- Evaluation of hepatic function effects on drug safety in post‑menopausal women
- Comparative analysis of drug exposure between impaired and healthy volunteers
With three active trials, the center supports the development of safer and more effective therapies by assessing how hepatic and renal conditions modify drug behavior.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Comac Medical Ltd.
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Adaptive, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SYX-5219 in Healthy Volunteers and Participants with Atopic Dermatitis | Sitryx Therapeutics Limited | Phase I | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 1 | Unknown | 2024-09-18 | 2024-09-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.